A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
מצבים רפואיים
Duchenne Muscular Dystrophy (DMD)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University Hospital Gent, Ghent, Belgium
Contact: Principal Investigator (Nicolas Deconinck)UZ Leuven, Leuven, Belgium
Contact: Principal Investigator (Liesbeth De Waele)Centre Hospitalier Régional de la Citadelle, Liège, Belgium
Contact: Principal Investigator (Aurore Daron)IRCCS Ospedale San Raffaele, Milan, Italy
Contact: Principal Investigator (Stefano Previtali)Fondazione Serena Onlus - Centro Clinico NeMO Milano, Milan, Italy
Contact: Study coordinator (Valeria Sansone) · valeria.sansone@centrocliniconemo.it · +39 3495607450Contact: Principal Investigator (Valeria Sansone)Ospedale Pediatrico Bambino Gesu, Rome, Italy
Contact: Principal Investigator (Adele D'Amico)Hospital Universitario Vall d'Hebron, Barcelona, Spain
Contact: Principal Investigator (David Gomez Andres)Hospital Sant Joan de Deu, Barcelona, Spain
Contact: Principal Investigator (Andres Nascimento)Leeds General Infirmary, Leeds, United Kingdom
Contact: Principal Investigator (Cristina Martos Lozano)Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
Contact: Principal Investigator (Rajesh Madhu)Great Ormond Street Hospital for Children, London, United Kingdom
Contact: Principal Investigator (Mariacristina Scoto)Royal Manchester Children's Hospital, Manchester, United Kingdom
Contact: Principal Investigator (Gary McCullagh)Freeman Hospital, Newcastle upon Tyne, United Kingdom
Contact: Principal Investigator (Michela Guglieri)Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Contact: Principal Investigator (Laurent Servais)
מובילי המחקר
Entrada Therapeutics Clinical Trials
Study Director
Entrada Therapeutics, Inc.